Drug Profile

BJT 628

Alternative Names: BJT-628

Latest Information Update: 06 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bluejay Therapeutics
Developer Mirum Pharmaceuticals
Class Antivirals; Small molecules
Mechanism of Action TENT4A protein inhibitors; TENT4B protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Hepatitis B; Hepatitis D

Most Recent Events

26 Jan 2026 Bluejay Therapeutics has been acquired and merged into Mirum Pharmaceuticals
11 Nov 2025 Pharmacokinetics and adverse events data from a phase I trial in Hepatitis B presented at the Liver Meeting 2025: 76^thAnnual Meeting of the American Association for the Study of Liver Diseases (AASLD-2025)
01 Jan 2025 Phase-I clinical trials in Hepatitis D in New Zealand, Australia (PO) (ACTRN12624001003561)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com